Page 1031 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

106. Wong HR, Wheeler DS, Tegtmeyer K, et al. Toward a clinically treatment of sepsis syndrome: a randomized, open-label, placebo-
feasible gene expression-based subclassifi cation strategy for sep- controlled multicenter trial. Crit. Care Med. 1994;22:12-21.
tic shock: proof of concept. Crit Care Med. 2010;38:1955-1961. 124. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of
107. Turrel-Davin F, Venet F, Monnin C, et al. mRNA-based approach antiinflammatory agents: retrospective and confirmatory stud-
to monitor recombinant gamma-interferon restoration of ies of sepsis. Am J Respir Crit Care Med. 2002;166:1197-1205.
LPS-induced endotoxin tolerance. Crit Care. 2011;15:R252.
125. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care
108. Cheadle WG. The human leukocyte antigens and their relation- Med. 1996;24:1125-1128.
ship to infection. Am J Surg. 1993;165:75S-81S.
126. Feezor RJ, Cheng A, Paddock HN, Baker HV, Moldawer LL.
109. Volk HD, Thieme M, Heym S, et al. Alterations in function Functional genomics and gene expression profiling in sepsis:
and phenotype of monocytes from patients with septic disease- beyond class prediction. Clin Infect Dis. 2005;41(suppl 7):S427-S435.
predictive value and new therapeutic strategies. Behring Inst
Mitt. 1991;88:208-215. 127. Wu JF, Ma J, Chen J, et al. Changes of monocyte human leuko-
cyte antigen-DR expression as a reliable predictor of mortality
110. Cheadle WG, Hershman MJ, Wellhausen SR, Polk HC Jr. in severe sepsis. Crit Care. 2011;15:R220.
HLA-DR antigen expression on peripheral blood monocytes
correlates with surgical infection. Am J Surg. 1991;161:639-645. 128. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al. Monocytic
HLA-DR expression in intensive care patients: interest for
111. Monneret G, Lepape A, Venet F. A dynamic view of mHLA-DR prognosis and secondary infection prediction. Crit Care Med.
expression in management of severe septic patients. Crit Care. 2009;37:2746-2752.
2011;15:198.
129. Cheron A, Floccard B, Allaouchiche B, et al. Lack of recovery
112. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin in monocyte human leukocyte antigen-DR expression is inde-
desensitization: involvement of interleukin-10 and transform- pendently associated with the development of sepsis after major
ing growth factor beta. J Exp Med. 1995;181:1887-1892.
trauma. Crit Care. 2010;14:R208.
113. Doecke WD, Syrbe U, Meinecke A, Platzer C, et al.
Improvement of monocyte function—a new therapeutic 130. Nierhaus A, Montag B, Timmler N, et al. Reversal of immu-
approach? In: Reinhart K, Eyrich K, and Sprung C, eds. Sepsis: noparalysis by recombinant human granulocyte-macrophage
Current Perspectives in Pathophysiology and Therapy. New colony stimulating factor in patients with severe sepsis. Intensive
York: Springer Verlag; 1994:473-500. Care Med. 2003;29:646-651.
114. Mills CD, Caldwell NM, Gann DJ. Evidence of a plasmamedi- 131. Ward NS, Casserly B, Ayala A. The compensatory anti-
ated “window” of immunodeficiency in rats following trauma. inflammatory syndrome (CARS) in critically-ill patients. Clin
J Clin Immunol. 1989;9:139-150. Chest Med. 2008;29(4):617-628.
115. Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in 132. Flohé SB, Agrawal H, Flohé S, et al. Diversity of interferon g and
the treatment of compensatory anti-inflammatory response granulocyte-macrophage colony-stimulating factor in restoring
syndrome. A new approach: proof of principle. Arch Intern Med. immune dysfunction of dendritic cells and macrophages in
1997;157:389-393. polymicrobial sepsis. Mol Med. 2008;14(5-6):247-256.
116. Flohe S, Scholz M. HLA-DR monitoring in the intensive care 133. Dries DJ, Jurkovich GJ, Maier RV, et al. Effect of interferon g
unit—more than a tool for the scientist in the laboratory? Crit on infection-related death in patients with severe injuries: a
Care Med. 2009;37(10):2849-2850. randomized, double-blind placebo-controlled trial. Arch Surg.
1994;129(10):1031-1041.
117. Ditschkowsk M, Kreuzfelder E, Rebmann V, et al. HLA-DR
expression and soluble HLA-DR levels in septic patients after 134. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G,
trauma. Ann Surg. 1999;229:246-254 Steinmann GG. Interferon-g in the prevention of severe burn-
related infections: a European Phase III multicenter trial. Crit
118. Wakefield CH, Carey PD, Foulds S, et al. Changes in major his-
tocompatibility complex class II expression in monocytes and Care Med. 1998;26(3):434-439.
T cells of patients developing infection after surgery. Br J Surg. 135. Stephens DP, Thomas JH, Higgins A, et al. Randomized,
1993;80:205-209. double-blind, placebo-controlled trial of granulocyte colony-
119. Venet F, Tissot S, Debard AL, et al. Decreased monocyte human stimulating factor in patients with septic shock. Crit Care Med.
leukocyte antigen-DR expression after severe burn injury: cor- 2008;36(2):448-454.
relation with severity and secondary septic shock. Crit Care 136. Mohammad RA. Use of granulocyte colony-stimulating factor
Med. 2007;35:1910-1917. in patients with severe sepsis and septic shock. Am J Health Syst
120. Flohe S, Lendemans S, Selbach C, et al. Effect of granulocyte- Pharm. 2010;67(15):1238-1245.
macrophage colonystimulating factor on the immune response 137. Schefold JC. Immunostimulation using granulocyte- and
of circulating monocytes after severe trauma. Crit Care Med. granulocyte-macrophage colony stimulating factor in patients
2003;31:2462-2469. with severe sepsis and septic shock. Crit Care. 2011;15:136.
121. Döcke WD, Höflich C, Davis KA, et al. Monitoring temporary 138. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony
immunodepression by flow cytometric measurement of mono- stimulating factor (G-CSF) and granulocyte-macrophage
cytic HLA-DR expression: a multicenter standardized study. colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.
Clinical Chem. 2005;51(12):2341-2347. Crit Care. 2011;15:R58.
122. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. 139. Meisel C, Schefold JC, Pschowski R, et al. Granulocytemacrophage
Novel therapies for sepsis: a review. J Trauma. 2005;58(4):867-874. colony-stimulating factor to reverse sepsis-associated immuno-
123. Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of suppression: a double-blind, randomized, placebo-controlled
human recombinant interleukin-1 receptor antagonist in the multicenter trial. Am J Respir Crit Care Med. 2009;180:640-648.

Section05-O-ref.indd 4 1/20/2015 4:51:16 PM